Iladatuzumab vedotin
Modify Date: 2025-08-26 09:12:03
Iladatuzumab vedotin structure
|
Common Name | Iladatuzumab vedotin | ||
|---|---|---|---|---|
| CAS Number | 1906205-77-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Iladatuzumab vedotinIladatuzumab vedotin (DCDS-0780A) is an antibody–drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research[1]. |
| Name | Iladatuzumab vedotin |
|---|
| Description | Iladatuzumab vedotin (DCDS-0780A) is an antibody–drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |